NHI.no
Annonse
Informasjon

Fettleversykdom, ikke-alkoholisk

Dette er en tilstand hvor det er økt mengde fettvev i leveren hos personer som ikke bruker alkohol, eller som bruker så lite alkohol at alkoholbruken ikke er noen sannsynlig forklaring på tilstanden.

Det er en tydelig sammenheng mellom overvekt, fedme, type 2 diabetes og fettleversykdom.

Sist oppdatert:

20. des. 2023

Dette dokumentet er basert på det profesjonelle dokumentet Fettleversykdom, ikke alkoholisk . Referanselisten for dette dokumentet vises nedenfor

  1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.; AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17. PMID: 36727674 PubMed
  2. Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic Steatohepatitis A Review. JAMA 2020; 323: 1175-83. doi:10.1001/jama.2020.2298 DOI
  3. Kaya E, Yilmaz Y. Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver. J Clin Transl Hepatol. 2022 Apr 28;10(2):329-338. Epub 2021 Oct 19. PMID: 35528971 PubMed
  4. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022. pmid:35798021 PubMed
  5. Stål P. Liver fibrosis in non-alcoholic fatty lliver disease - diagnostic challenge with prognostic significance. World J Gastroenterol 2015; 21: 11077-87. doi:10.3748/wjg.v21.i39.11077 DOI
  6. Kanwal F, Shubrook JH, Adams LA, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2021; 161: 1657-69. pmid:34602251 PubMed
  7. Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2023. pmid:36400097 PubMed
  8. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466. Epub 2017 Dec 1. PMID: 28802062 PubMed
  9. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022; 28: 528-562. pmid:35569886 PubMed
  10. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263-2273. PubMed
  11. Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 2022; 10: 284-296. pmid:35183303 PubMed
  12. Baker JL, Farpour-Lambert NJ, Nowicka P, Pietrobelli A, Weiss R. Evaluation of the overweight/obese child - practical tips for the primary health care provider: recommendations from the Childhood Obesity Task Force of the European Association for the Study of Obessity. Obes Facts 2010; 3: 131-7. PubMed
  13. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents. JAMA 2011; 305: 1659-68. Journal of the American Medical Association
  14. DiNicolantonio JJ, Subramonian AM, O'Keefe JH. Added fructose as a principal driver on non-alcoholic fatty liver disease: a public health crisis. Open Heart 2017. pmid:29118995 PubMed
  15. Diehl AM, Day C. Cause, pathogenesis, and treatment of Non-alcoholic steatohepatitis. N Eng J Med 2017; 377: 2063-72. pmid:29166236 PubMed
  16. Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. New Engl J Med 2010; 362: 1082-9. PubMed
  17. Castera L, Laouenan C, Vallet-Pichard A, et al. High prevalence of NASH and advanced fibrosis in type 2 diabetes: A prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold. Diabetes Care 2023. PMID: 37043830 PubMed
  18. Mulabecirovic A, Havre RF, Vesterhus M, Gilja OH. Diagnostiske metoder i hepatologi: Ultralyd, Elastografi, CEUS, og Leverbiopsi. Indremedisineren, publisert 24.01.2019. indremedisineren.no
  19. Koot BG, van der Baan-Slootweg OH, Bohte AE, et al. Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. Obesity 2013; 21: 583-90. pmid:23592667 PubMed
  20. Paul S, Davis AM. JAMA Clinical Guidelines Synopsis. Diagnosis and management of Nonalcoholic Fatty Liver Disease. JAMA 2018. doi:10.1001/jama.2018.17365 DOI
  21. Koutoukidis DA, Astbury NM, Tudor KE, et al. Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease A Systematic Review and Meta-analysis. JAMA Intern Med 2019. pmid:31260026 PubMed
  22. van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H. The effects of physical exercise on fatty liver disease. Gene Expr. 2018;18(2):89-101. PMID: 29212576 PubMed
  23. Duell PB, Welty FK, Miller M, et al.; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022 Jun;42(6):e168-e185. doi: 10.1161/ATV.0000000000000153. Epub 2022 Apr 14. PMID: 35418240 PubMed
  24. Dufour JF, Anstee QM, Bugianesi E, et al.; Current therapies and new developments in NASH. Gut. 2022 Jun 16;71(10):2123–34. doi: 10.1136/gutjnl-2021-326874. Epub ahead of print. PMID: 35710299 PubMed
  25. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121. PubMed
  26. Wong VW-S, Wong GL-H, Choi PC-L, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-74. Gut
  27. Zhang HJ, He J, Pan LL, et al. Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial. JAMA Intern Med. 2016. doi: 10.1001/jamainternmed.2016.3202. DOI
  28. Kenneally S, Sier JH, Moore JB. Efficacy of dietary and physical acticity intervention in non-alcoholic fatty liver disease. BMJ Open Gastroenterol 2017; 4: e000139. pmid:28761689 PubMed
  29. Wei X, Lin B, Huang Y, et al. Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease The TREATY-FLD Randomized Clinical Trial. JAMA Netw Open 2023. pmid:36930148 PubMed
  30. David D, Eapen CE. What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease? J Clin Exp Hepatol. 2021 Mar-Apr;11(2):232-238. doi: 10.1016/j.jceh.2020.09.001. Epub 2020 Sep 3. PMID: 33746449 PubMed
  31. Mireku A. NASH drugs race to cross the finish line. Pharmaceutical Technology; Features. Published June 26, 2023. www.pharmaceutical-technology.com
  32. Shah S, Shiekh Y, Lawrence JA, Ezekwueme F, Alam M, Kunwar S, Gordon DK. A Systematic Review of Effects of Vitamin E on the Cardiovascular System. Cureus. 2021 Jun 12;13(6):e15616. doi: 10.7759/cureus.15616. PMID: 34277234 PubMed
  33. Jang H, Kim Y, Lee DH, et al. Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease. JAMA Intern Med 2024. pmid:38345802 PubMed
  34. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85. New England Journal of Medicine
  35. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazon treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus. Ann Intern Med 2016; 165: 305-15. pmid:27322798 PubMed
  36. Singh S, Kera R, Allen AM, et al. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology 2015. PMID: 26189925 PubMed
  37. Musso G, Cassader M, Paschetta E, et al. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017. PMID: 28241279 PubMed
  38. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-57. pmid:28714183 PubMed
  39. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med 2023; 390: 497-509. pmid:38324483 PubMed
  40. Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2014; 39:1276. PMID: 24738701 PubMed
  41. Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double blind randomised controlled clinical trial. Arch Dis Child 2011; 96: 350-3. PubMed
  42. Shouhed D, Steggerda J, Burch M, Noureddin M. The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2018; 9: 797-811. pmid:28712339 PubMed
  43. Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149(2):379-388. PMID: 25917783 PubMed
  44. Aminian A, Al-Kurd A, Wilson R, et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA 2021; 326: 2031-42. pmid:34762106 PubMed
  45. Verrastro O, Panunzi S, Castagneto-Gessey L, et al. Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 2023. pmid:37088093 PubMed
  46. Elsaid MI, Li Y, Bridges JFP, et al. Association of Bariatric Surgery With Cardiovascular Outcomes in Adults With Severe Obesity and Nonalcoholic Fatty Liver Disease. JAMA Netw Open 2022; 5: e2235003. doi:10.1001/jamanetworkopen.2022.35003 DOI
  47. Krishnan A, Hadi Y, Alqahtani SA, et al. Cardiovascular Outcomes and Mortality After Bariatric Surgery in Patients With Nonalcoholic Fatty Liver Disease and Obesity. JAMA Netw Open 2023. pmid:37027156 PubMed
  48. Sanyal A, Natta MLV, Clark J, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med 2021; 385: 1559-69. pmid:34670043 PubMed
  49. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371. PubMed
  50. Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1224. PubMed
  51. Kim GA, Lee HC, Choe J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2017 PMID: 29150142 PubMed
  52. Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021. pmid:34555346 PubMed
  53. Kim KS, Hong S, Han K, Park CY. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: Nationwide population based study.. BMJ 2024; 384: e076388. pmid:38350680 PubMed
  54. de Avila L, Henry L, Paik JM, et al. Nonalcoholic Fatty Liver Disease Is Independently Associated With Higher All-Cause and Cause-Specific Mortality. Clin Gastroenterol Hepatol 2023; 21: 2588-2596. pmid:36646233 PubMed
  55. Ebrahimi F, Simon TG, Hagström H, et al. Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease - A Population-based Cohort Study. Clin Gastroenterol Hepatol 2023; 21: 3346-3355. pmid:37245712 PubMed
  56. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: A follow up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74. PubMed
  57. Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a commin cause of progressive chronic liver injury?. J Clin Pathol 2002; 55: 689. PubMed
  58. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356. PubMed
  59. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73. PubMed
  60. Wilkins T, Tadkod A, Hepburn I, Schade RR. Nonalcoholic fatty liver disease: diagnosis and management. Am Fam Physician 2013; 88: 35-42. American Family Physician
Annonse
Annonse